LOGIN  |  REGISTER
Viking Therapeutics
Recursion

Option Care Health to Participate in Upcoming Investor Conferences

May 01, 2025 | Last Trade: US$32.76 0.20 -0.61

BANNOCKBURN, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will participate in the following upcoming investor conferences:

  • The Bank of America Healthcare Conference, being held in Las Vegas, on Tuesday, May 13, 2025, including a presentation at 8:00am PT/11:00am ET.
  • The William Blair 45th Annual Growth Stock Conference, being held in Chicago, on Tuesday, June 3, 2025, including a presentation at 11:20am CT/12:20pm ET.
  • The Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, on Monday, June 9, 2025, including a fireside chat at 2:00pm ET.

Webcast links and related presentation materials will be available online at https://investors.optioncarehealth.com.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.

For Investor Inquiries:

Mike Shapiro
Chief Financial Officer
T: (312) 940-2538
This email address is being protected from spambots. You need JavaScript enabled to view it.

Viking Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page